Aviceda Therapeutics

Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases. The company focused on the next generation of immuno-modulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly. A combination of cutting-edge technologies and deep biological insights form Aviceda’s engine of transformative product creation. Aviceda uses their cell-based high-throughput screening (HTS) platform, they can rapidly screen, select, and optimize ligands based on maximum affinity and specificity for each different type of innate immune cell. . The company's products are for eye diseases, fibrosis, neurology, and oncology, for eye diseases like AVD-104, AVD-302, AVD-401 for dry eye, diabetic retinopathy and retinoblastoma respectively AVD-601, AVD-701 and AVD-801 for oncology, neurology and fibrosis respectively, enabling patients to address the innate immune system and chronic non-resolving inflammation. It was founded in 2018 and is headquartered in Cambridge, MA, USA.

show less